Legend Biotech USA, Inc.

Legend Biotech USA, Inc. is a United States-based biotechnology company specializing in the research, development, and commercialization of advanced cell and gene therapies. As a key subsidiary of Legend Biotech Corporation, it plays a crucial role in the company's global operations, particularly in advancing chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies.

The company is notably involved in the development of CARVYKTI, also known as ciltacabtagene autoleucel, a BCMA-targeted CAR-T product. Through a December 2017 exclusive worldwide license and collaboration agreement with Janssen Biotech, Legend Biotech USA, Inc. contributes to the clinical development and potential commercialization of this innovative treatment for patients with relapsed or refractory multiple myeloma.

Operating primarily from its facilities in New Jersey, the company focuses on leveraging cutting-edge technologies to address unmet medical needs in oncology. Its activities include conducting clinical trials, manufacturing cell therapies, and navigating regulatory pathways in the US market.

As part of the Legend Biotech group, which has roots in China and a presence on international stock exchanges, Legend Biotech USA, Inc. helps bridge Eastern and Western biotech innovation. The company positions itself in the competitive landscape of cell therapy, where it collaborates with major pharmaceutical partners to bring novel treatments to patients worldwide. Its efforts underscore the growing importance of personalized medicine in cancer care.